Exelixis Accounts Payable 2010-2025 | EXEL

Exelixis accounts payable for the quarter ending June 30, 2025 were $0.026B, a 9.96% decline year-over-year.

  • Exelixis accounts payable for 2024 were $0.038B, a 13.1% increase from 2023.
  • Exelixis accounts payable for 2023 were $0.034B, a 3.37% increase from 2022.
  • Exelixis accounts payable for 2022 were $0.033B, a 34.66% increase from 2021.

Exelixis Accounts Payable 2010-2025 | EXEL

  • Exelixis accounts payable for 2024 were $0.038B, a 13.1% increase from 2023.
  • Exelixis accounts payable for 2023 were $0.034B, a 3.37% increase from 2022.
  • Exelixis accounts payable for 2022 were $0.033B, a 34.66% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$248.1B
Amgen (AMGN)$153.8B
Gilead Sciences (GILD)$139.7B
Vertex Pharmaceuticals (VRTX)$100.5B
Bristol Myers Squibb (BMY)$95.4B
GSK (GSK)$80.3B
CSL (CSLLY)$66.8B
Regeneron Pharmaceuticals (REGN)$61.4B
Alnylam Pharmaceuticals (ALNY)$59.3B
Argenex SE (ARGX)$43.1B
Insmed (INSM)$28.5B
BioNTech SE (BNTX)$24.5B
Royalty Pharma (RPRX)$20.8B
Biogen (BIIB)$19.4B
Genmab (GNMSF)$16.4B
Incyte (INCY)$16.3B
Genmab (GMAB)$16.1B
Illumina (ILMN)$15.2B
Ascendis Pharma (ASND)$11.9B
BioMarin Pharmaceutical (BMRN)$11.1B
Swedish Orphan Biovitrum (BIOVF)$10.9B
QIAGEN (QGEN)$10.3B
Moderna (MRNA)$9.5B
Verona Pharma American Depositary Share (VRNA)$9.2B
Exact Sciences (EXAS)$8.9B
Bio-Techne Corp (TECH)$8.5B
Halozyme Therapeutics (HALO)$8.5B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8.2B
Guardant Health (GH)$8B